Evommune EVMN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.07M-60.7% | $2.72M+173% | $997.63K— | —— | $213.63K+3.3% | ||
| $372.71K-28.1% | $518.47K+481% | $89.21K— | —— | -$5.84K-102% | ||
| $1.59M+2.7% | $1.55M-8.4% | $1.69M— | —— | $111.14K-93.5% | ||
| $3.4M-34.5% | $5.19M+23.2% | $4.21M— | —— | —— | ||
| $32.8K-12.3% | $37.38K-11.2% | $42.09K— | —— | —— | ||
| $818.14K0.0% | $818.14K0.0% | $818.14K— | —— | —— | ||
| $150.18K-7.1% | $161.71K-64.9% | $461.3K— | —— | —— | ||
| $3.82M-2.7% | $3.92M-2.5% | $4.02M— | —— | —— | ||
| $7.21M-20.8% | $9.11M+10.6% | $8.23M— | —— | —— | ||
| $622.22K-6.9% | $668.22K-54.2% | $1.46M— | —— | —— | ||
| $142.28K-8.2% | $154.96K+4,210% | $3.6K— | —— | —— | ||
| —— | $154.96K— | —— | —— | —— | ||
| $2.84M-50.6% | $5.75M+0.8% | $5.7M— | —— | —— | ||
| $139.57K-0.6% | $140.47K-0.6% | $141.33K— | —— | —— | ||
| $8.89M+389% | $1.82M-5.7% | $1.93M— | —— | —— | ||
| $11.72M+54.9% | $7.57M-0.8% | $7.63M— | —— | —— | ||
| 220M0.0% | 220M0.0% | 220M— | —— | —— | ||
| -$14.05M-101% | -$6.98M+10.0% | -$7.75M— | —— | —— | ||
| -$4.51M-393% | $1.54M+155% | $604.67K+135% | $257.16K+68.1% | $153.01K+229% | ||
| $7.21M-20.8% | $9.11M+10.6% | $8.23M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Evommune 's total assets?
- Evommune (EVMN) holds $7.2M in total assets.
- How much debt does Evommune have?
- Evommune carries $2.0M in total debt against -$4.5M of shareholders' equity, a debt-to-equity ratio of 1.36.
- How much cash does Evommune have?
- Evommune holds $1.1M in cash and equivalents.
- Can Evommune cover its short-term obligations?
- Its current ratio is 1.20 — current assets exceed current liabilities.
- Where does Evommune 's balance sheet data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
